Genomate Health has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

Genomate Health builds powerful computational models that harness the knowledge of published scientific evidence and clinical experience, augmented with computational reasoning. These models enable AI-guided treatment based on each patient’s unique disease. Our flagship product, Genomate®, is the first clinically validated universal computational reasoning model that can predict response to multiple targeted therapies by analyzing each patient's unique combinations of genetic alterations and biomarkers. Genomate® delivers the first computational reasoning solution to implement the true promise of precision oncology of N-of-1 therapy based on the genomic profile of the patient’s tumor. The result is presented as a comprehensive, data-backed report that guides oncologists and patients toward the most suitable treatment, enhancing the efficacy of therapies.

Genomate Health's decision to join the NVIDIA Inception program is a strategic move that will expedite the development of Genomate®. The program's provisions, including access to cutting-edge technology, training, and go-to-market support, will be instrumental in optimizing our algorithms and computational workflows, bolstering our data analysis capabilities, and significantly shortening the time to market for our innovative products. Moreover, the program presents a unique opportunity for Genomate Health to collaborate with industry-leading experts and other AI-driven organizations, fostering a network of innovation and growth.

"Joining the NVIDIA Inception program is a significant milestone for Genomate Health," said Istvan Petak, Founder, CEO and CSO of Genomate Health. "The access to NVIDIA's cutting-edge technology and expertise will be instrumental in accelerating our mission to revolutionize precision medicine. We are excited about the opportunities this partnership brings to collaborate with other innovators in the AI and healthcare space.” 

Barbara Vodicska, Head of Translational Science at Genomate Health, added “It's crucial to bridge the gap between groundbreaking scientific research and practical clinical applications. Having access to NVIDIA’s cutting-edge technology and resources will be pivotal in advancing our computational models and translating our research into impactful patient outcomes. It will empower our team to push the boundaries of what is possible in precision oncology, allowing us to harness the full potential of AI to provide more accurate, personalized, and effective treatment options for cancer patients.”

‍

NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.

By joining NVIDIA Inception, Genomate Health is poised to advance its mission of making personalized medicine a reality, ultimately improving patient outcomes and transforming the future of healthcare. This partnership marks a significant step towards empowering clinicians to make data-driven decisions that enhance patient care and drive forward the next generation of cancer treatments.